Overview and Scope
Biopharmaceutical contract manufacturing refers to a process in which a biopharmaceutical company hires a third-party manufacturer to produce its drugs or biologic products on its behalf. It is utilized when pharmaceutical businesses employ the facilities of other companies to manufacture pharmaceuticals under their own brand. It is identical to private label or third-party production.
Sizing and Forecast
The biopharmaceuticals contract manufacturing market size has grown rapidly in recent years. It will grow from $18.31 billion in 2023 to $20.23 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to increased biopharmaceutical development, cost efficiency and risk mitigation, growing pipeline of biologics, globalization of biopharmaceutical industry, flexible manufacturing solutions.
The biopharmaceuticals contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $29.97 billion in 2028 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing outsourcing trends, biosimilar development, shorter time-to-market requirements, global market expansion, focus on specialized services. Major trends in the forecast period include technological integration, outsourcing expansion beyond large molecules, advanced manufacturing technologies adoption, focus on quality and compliance, rise of biosimilars manufacturing, .
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report
Segmentation & Regional Insights
The biopharmaceuticals contract manufacturing market covered in this report is segmented –
1) By Product: Biologics, Monoclonal Antibodies (MABs), Recombinant Proteins, Vaccines, Antisense, RNAi, And Molecular Therapy, Biosimilars
2) By Source: Mammalian, Non-mammalian
3) By Service: Process Development, Fill And Finish Operations, Analytical And QC studies, Packaging
4) By Application: Clinical, Commercial
North America was the largest region in the biopharmaceutical contract manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global biopharmaceuticals contract manufacturing market forecast period. The regions covered in the biopharmaceuticals contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10181&type=smp
Major Driver Impacting Market Growth
The increasing demand for biologics is expected to propel the growth of the biopharmaceutical contract manufacturing market going forward. Biologics are products manufactured from living organisms or containing pieces made from them, such as those derived from humans, animals, or microbes, using biotechnology. They are utilized to treat various diseases and ailments and provide the most cutting-edge therapies currently available. The biologics contract manufacturing industry is expanding due to the expanding biologics pipeline, the complexity of the production process, and firms focusing on their core capabilities, several pharmaceutical and biotechnology businesses are currently outsourcing a wide range of tasks, from commercial-scale manufacturing to early-stage drug research. For instance, in December 2021, IQVIA Inc, a US-based provider of commercial outsourcing and biopharmaceutical development services, released a report stating that by 2021, biologics will account for 34% of all medical expenditures in Europe, with a value of €78.6 billion (US $86.29 billion) with a five-year compound annual growth rate (CAGR) of 10.5%. Therefore, the increasing demand for biologics is driving the growth of the biopharmaceutical contract manufacturing market.
Key Industry Players
Major companies operating in the biopharmaceuticals contract manufacturing market report are Boehringer Ingelheim GmbH, Lonza Group Ltd., Inno Biologics Sdn Bhd, Rentschler Biopharma SE, Samsung Biologics Co. Ltd., AGC Biologics, ProBioGen AG, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific Inc., Binex Co. Ltd., AbbVie Inc., Catalent Inc, Pfizer Inc., Merck KGaA, Pressure BioSciences, Novartis International AG, Cambrex Corporation, Emergent BioSolutions Inc., JRS Pharma GmbH & Co. KG, WuXi Biologics, Siegfried Holding AG, Toyobo Co. Ltd., ADMA Biologics Inc., UCB S.A., AstraZeneca PLC, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Shire Pharmaceuticals LLC, Baxter International Inc., Becton Dickinson and Company, Polyphor Ltd., Patheon Inc., Alcami Corporation
The biopharmaceuticals contract manufacturing market report table of contents includes:
1. Executive Summary
- Biopharmaceuticals Contract Manufacturing Market Characteristics
- Biopharmaceuticals Contract Manufacturing Market Trends And Strategies
- Biopharmaceuticals Contract Manufacturing Market – Macro Economic Scenario
- Global Biopharmaceuticals Contract Manufacturing Market Size and Growth
.
- Global Biopharmaceuticals Contract Manufacturing Market Competitive Benchmarking
- Global Biopharmaceuticals Contract Manufacturing Market Competitive Dashboard
- Key Mergers And Acquisitions In The Biopharmaceuticals Contract Manufacturing Market
- Biopharmaceuticals Contract Manufacturing Market Future Outlook and Potential Analysis
- Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
